| Document |
Document Title |
|
JP2009073845A |
To provide a composition and method for identifying a molecule of a potent inhibitor on axon regeneration in myelin, and blocking or operating a MAG active level in the neural system to treat a patient having injuries to a neural system ...
|
|
JP4247775B2 |
C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or proteoglycans, advantageously proteoglycans con...
|
|
JP2009057387A |
To provide a method for producing an anti-inflammatory agent exhibiting high pharmacological activity, no side effect, and high safety by using natural products as raw materials.The method for producing an anti-inflammatory agent for ext...
|
|
JP4232461B2 |
|
|
JP4224998B2 |
|
|
JP4222012B2 |
|
|
JP4215278B2 |
The present invention relates to novel pyranoside derivatives having general formula (I), process for the manufacture thereof and their use as medicaments.
|
|
JP4209957B2 |
|
|
JP2008542202A |
Compounds of the formula: are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.
|
|
JP2008540573A |
4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed.
|
|
JP4178927B2 |
|
|
JP2008266215A |
To provide a new therapeutic agent useful for therapy and prevention of several ischemic diseases.The promotor for vascularization after ischemia comprises a quercetin glucoside represented by general formula (1) (wherein, Glc represents...
|
|
JP2008239625A |
To provide a medicine composition for promoting healing of a hurt accompanied by reduction of scars or a fibrous disorder.The medicine composition composed of fructose-1-phosphate as an active ingredient, a pharmaceutically acceptable ca...
|
|
JP4156035B2 |
There are provided according to the invention novel compounds of formula Iwherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment ...
|
|
JP4153057B2 |
Trehalose is oxidized to give oxidized trehalose which then is hydrolyzed to produce D-glucuronolactone which is thereafter recovered to realize high-yield and low-cost production of D-glucuronolactone.
|
|
JP2008185373A |
To provide a method which enables the simple analyzation of a composition containing an acidic oligosaccharide such as an oligosaccharide containing fucose obtained by hydrolyzing fucoidin, especially a disaccharide or above oligosacchar...
|
|
JP2008162944A |
To readily and inexpensively provide an acidic oligosaccharide having a high content of uronic acid in mass.The method for producing the acidic oligosaccharide having the uronic acid residue in the molecule includes extracting a corn fib...
|
|
JP4121044B2 |
|
|
JP2008136376A |
To provide a simple method for producing an acidic xylooligosaccharide, by which the acidic xylooligosaccharide having 2-5 average polymerization degree of xylose can be produced in large amount, as well as, at low cost.The acidic xylool...
|
|
JP4073787B2 |
An enzyme which decomposes a sulfated fucoglucuronomannan and is useful in the field of glycotechnology; a process for producing the enzyme; a fucoidan fraction reduced in the number of the kinds of molecules and useful as a reagent in g...
|
|
JP4070817B2 |
Chromogenic and fluorogenic 4,7-dialkoxy-N-acetylneuraminic acid substrates of the general formula l groups containing 1 to 4 carbon atoms and R3 is a chromogenic or fluorogenic group. These substrates can be used to detect influenza typ...
|
|
JP2008063237A |
To provide a highly safe antitumor agent having excellent antitumor effects.The antitumor agent is characterized as comprising an acidic xylooligosaccharide having a uronic acid residue in the xylooligosaccharide molecule. The acidic xyl...
|
|
JP4060079B2 |
A process for the preparation of 1,5-dideoxy-1,5-imino hexitols of a hexose sugars from novel hydroxyl protected oxime intermediates. The process includes formation of a lactam which is reduced to the hexitol. The hexitols are useful as ...
|
|
JP2008506734A |
D-Xylopyranosyl-substituted phenyls of general formula I wherein the groups R1 to R5, X, Z and R7a, R7b, R7c are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention a...
|
|
JP2008037800A |
To provide a new benzoazepine compound having vasopressin antagonism.This benzoazepine compound represented by the general formula (1) [R1 is H; R2 is -O-R4 or -N(R5)-O-R6; or R1 and R2 together represent a =N(R7)O; R3 is a lower alkyl; ...
|
|
JP2008504840A |
One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present inventi...
|
|
JPWO2005092348A1 |
In the present invention, a uronic acid residue (uronic acid indicates iduronic acid or glucuronic acid; hereinafter the same applies to uronic acid) and a glucosamine residue are α1,4-glycoside bond or β1,4-glycoside bond. 2 sugars, o...
|
|
JP4041856B2 |
|
|
JP2007524572T6 |
It has formula (I) and they are inside of a formula, and R.2It is は水素, monomer glycoside, or oligomer glycoside, and is R.3it is a basis which has は水素, monomer glycoside, oligomer glycoside, or formula (II), and R is low-grad...
|
|
JP4034364B2 |
|
|
JP2008001711A |
To provide a method for preparation of 1,5-dideoxy-1,5-imino hexitols of hexose sugars from new hydroxy group-protected oxime intermediates.The method includes the processes of (a) reacting an acid ester or a hydrazide of a 5-hexulosonic...
|
|
JP4022659B2 |
|
|
JP4005115B1 |
Disclosed is an analgesic agent for a non-inflammatory pain disease, which comprises a sialic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The sialic acid which is an active ingredient for the agent has an ...
|
|
JP2007530417A |
Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contac...
|
|
JP2007277258A |
To provide a treating agent or prevention agent for inflammation and a treating agent or prevention agent for neurological disorder. The medicine contains a hyaluronan as an active component. The hyaluronan is preferably a tetrose (HA4) ...
|
|
JP2007277164A |
To provide an allergic rhinitis-improving agent for internal application, which is excellent in an allergic rhinitis-improving effect and has high safety. This allergic rhinitis-improving agent for the internal application contains a Lyo...
|
|
JP2007262103A |
To provide a remedy for osteoarthritis containing a hyaluronan as an active ingredient. The drug contains a hyaluronan as the active ingredient. Preferably, the hyaluronan is a tetrasaccharide (HA4) containing 2 units of a unit composed ...
|
|
JP3989808B2 |
|
|
JP2007238492A |
To provide a compound useful as an agrochemical (especially, as an agricultural or horticultural insecticide and/or acaricide). This agrochemical contains a polyether compound A-96625 expressed by formula (1) or its salts as an active in...
|
|
JP2007236264A |
To provide 3D-(3,5/4)-trihydroxycyclohexane-1,2-dione hydrolase, 5-deoxy-D-glucuronic acid and a method for producing the same; and also to provide a method for producing a γ-lactone derived from 5-deoxy-D-glucuronic acid. 5-deoxy-D-glu...
|
|
JP2007524572A |
Disclosed are compounds having the formula wherein R2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula R is a lower alkylene, R' ...
|
|
JP2007520453A |
4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to s...
|
|
JP3947218B2 |
This invention relates to an improved process for the synthesis of 4-alkoxy-N-acetylneuraminic acids. According to the process of the invention, N-acetylneuraminic acid is first alkylated at C-1 and C-2 and then the vicinal hydroxyl grou...
|
|
JP3943082B2 |
|
|
JP3939592B2 |
To provide a method for producing an oligosaccharide (salt), capable of producing the oligosaccharide or its salt in a high yield, without causing discoloration of the oligosaccharide (salt), nor change in chemical structure thereof due ...
|
|
JP3932679B2 |
To provide a method for producing polyguluronic acid having low polymerization degree of ≤20 and practically free from contaminant of mannuronic acid by an industrially advantageous process in high yield. The organic base salts of alig...
|
|
JP3934047B2 |
Processes for the preparation of pyrrolidones and pyrrolidines from tri-O-acetyl-D- erythro -4-pentulosonic acid esters are described. The compounds are aza sugar analogs of D-ribofuranoside and are intermediates to drugs which regulate ...
|
|
JP3933870B2 |
A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.
|
|
JP3930559B2 |
A medicinal composition containing a sialic acid derivative as the active ingredient and usable as an antiviral agent, diarrhea remedy, antiulcer agent, antiinflammatory agent, antiallergic agent and bifidus growth accelerator. A process...
|
|
JP2007513912A |
A method for the production of C1-C10-alkyl 2-keto-L-gulonates by esterification of 2-keto-L-gulonic acid anhydrate with an anhydrous C1-C10-alkyl alcohol in the presence of an acidic homogeneous catalyst in a reactor cascade comprising ...
|
